Welcome to Paid Research Studies




  • Conditions:   Medulloblastoma;   Astrocytoma, Grade III;   Glioblastoma;   Anaplastic Astrocytoma;   Brain Stem Neoplasms, Malignant;   Oligodendroblastoma;   Anaplastic Oligodendroglioma;   Malignant Glioma
    Intervention:   Drug: Mebendazole
    Sponsor:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Recruiting

  • Conditions:   Pilomyxoid Astrocytoma;   Pilocytic Astrocytoma;   Glioma, Astrocytic;   Optic Nerve Glioma;   Pleomorphic Xanthoastrocytoma;   Glioblastoma Multiforme;   Anaplastic Astrocytoma;   Gliosarcoma;   Diffuse Intrinsic Pontine Glioma;   DIPG;   Low-grade Glioma;   Brainstem Glioma
    Interventions:   Drug: Mebendazole;   Drug: Vincristine;   Drug: Carboplatin;   Drug: Temozolomide;   Drug: Bevacizumab;   Drug: Irinotecan
    Sponsors:   Julie Krystal;   Janssen Pharmaceuticals
    Recruiting

  • Conditions:   Healthy Subject;   Intracranial Neoplasm;   Recurrent Glioblastoma
    Interventions:   Drug: Fluorine F 18 DASA-23;   Procedure: Positron Emission Tomography
    Sponsor:   Sanjiv Sam Gambhir
    Recruiting

  • Conditions:   Recurrent B Acute Lymphoblastic Leukemia;   Refractory B Acute Lymphoblastic Leukemia
    Interventions:   Drug: Palbociclib;   Drug: Dexamethasone
    Sponsors:   Sidney Kimmel Cancer Center at Thomas Jefferson University;   Pfizer
    Recruiting

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia in Remission;   Chronic Lymphocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Cytomegalovirus Positive;   Hematopoietic Cell Transplant Recipient;   Hodgkin Lymphoma;   Lymphadenopathy;   Lymphoblastic Lymphoma;   Myelodysplastic Syndrome;   Myelofibrosis;   Myeloproliferative Neoplasm;   Non-Hodgkin Lymphoma
    Interventions:   Drug: Letermovir;   Biological: Multi-peptide CMV-Modified Vaccinia Ankara Vaccine;   Other: Placebo
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Advanced Malignant Solid Neoplasm;   EGFR Gene Amplification;   EGFR Gene Mutation;   ERBB2 Gene Amplification;   ERBB2 Gene Mutation;   ERBB3 Gene Mutation;   ERBB4 Gene Mutation;   KRAS Gene Mutation;   Metastatic Malignant Solid Neoplasm;   Refractory Malignant Solid Neoplasm
    Interventions:   Drug: Everolimus;   Drug: Neratinib;   Drug: Palbociclib;   Drug: Trametinib
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Advanced Malignant Solid Neoplasm;   RB1 Positive;   Recurrent Childhood Ependymoma;   Recurrent Ewing Sarcoma;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Kidney Wilms Tumor;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Glioma;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdoid Tumor;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Refractory Ependymoma;   Refractory Ewing Sarcoma;   Refractory Glioma;   Refractory Hepatoblastoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Glioma;   Refractory Medulloblastoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Peripheral Primitive Neuroectodermal Tumor;   Refractory Rhabdoid Tumor;   Refractory Rhabdomyosarcoma;   Refractory Soft Tissue Sarcoma
    Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Palbociclib;   Other: Pharmacological Study
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   KRAS Gene Mutation;   Metastatic Colorectal Carcinoma;   NRAS Gene Mutation;   Stage III Colorectal Cancer AJCC v8;   Stage IIIA Colorectal Neuroendocrine Tumor AJCC v8;   Stage IIIB Colorectal Cancer AJCC v8;   Stage IIIC Colorectal Cancer AJCC v8;   Stage IV Colorectal Cancer AJCC v8;   Stage IVA Colorectal Cancer AJCC v8;   Stage IVB Colorectal Cancer AJCC v8;   Stage IVC Colorectal Cancer AJCC v8;   Unresectable Carcinoma
    Interventions:   Drug: Binimetinib;   Drug: Palbociclib;   Drug: Trifluridine and Tipiracil Hydrochloride
    Sponsors:   Academic and Community Cancer Research United;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   Childhood Langerhans Cell Histiocytosis;   Histiocytic Sarcoma;   Juvenile Xanthogranuloma;   Malignant Glioma;   Recurrent Central Nervous System Neoplasm;   Recurrent Childhood Ependymoma;   Recurrent Childhood Malignant Germ Cell Tumor;   Recurrent Childhood Medulloblastoma;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Solid Neoplasm;   Recurrent Neuroblastoma;   Recurrent Osteosarcoma;   Recurrent Peripheral Primitive Neuroectodermal Tumor;   Recurrent Rhabdoid Tumor;   Refractory Central Nervous System Neoplasm;   Refractory Childhood Malignant Germ Cell Tumor;   Refractory Ewing Sarcoma;   Refractory Glioma;   Refractory Hepatoblastoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Solid Neoplasm;   Refractory Medulloblastoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Peripheral Primitive Neuroectodermal Tumor;   Refractory Rhabdoid Tumor;   Refractory Rhabdomyosarcoma;   Rhabdoid Tumor;   Stage III Osteosarcoma AJCC v7;   Stage III Soft Tissue Sarcoma AJCC v7;   Stage IV Osteosarcoma AJCC v7;   Stage IV Soft Tissue Sarcoma AJCC v7;   Stage IVA Osteosarcoma AJCC v7;   Stage IVB Osteosarcoma AJCC v7;   Wilms Tumor
    Interventions:   Procedure: Biopsy;   Procedure: Biospecimen Collection;   Drug: Ensartinib;   Drug: Erdafitinib;   Other: Laboratory Biomarker Analysis;   Drug: Larotrectinib;   Procedure: Mutation Carrier Screening;   Drug: Olaparib;   Drug: Palbociclib;   Other: Pharmacological Study;   Drug: Samotolisib;   Drug: Selumetinib Sulfate;   Drug: Tazemetostat;   Drug: Ulixertinib;   Drug: Vemurafenib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Advanced Malignant Solid Neoplasm;   Bladder Carcinoma;   Breast Carcinoma;   Cervical Carcinoma;   Colon Carcinoma;   Colorectal Carcinoma;   Endometrial Carcinoma;   Esophageal Carcinoma;   Gastric Carcinoma;   Glioma;   Head and Neck Carcinoma;   Kidney Carcinoma;   Liver and Intrahepatic Bile Duct Carcinoma;   Lung Carcinoma;   Lymphoma;   Malignant Uterine Neoplasm;   Melanoma;   Ovarian Carcinoma;   Pancreatic Carcinoma;   Plasma Cell Myeloma;   Prostate Carcinoma;   Rectal Carcinoma;   Recurrent Bladder Carcinoma;   Recurrent Breast Carcinoma;   Recurrent Cervical Carcinoma;   Recurrent Colon Carcinoma;   Recurrent Colorectal Carcinoma;   Recurrent Esophageal Carcinoma;   Recurrent Gastric Carcinoma;   Recurrent Glioma;   Recurrent Head and Neck Carcinoma;   Recurrent Liver Carcinoma;   Recurrent Lung Carcinoma;   Recurrent Lymphoma;   Recurrent Malignant Solid Neoplasm;   Recurrent Melanoma;   Recurrent Ovarian Carcinoma;   Recurrent Pancreatic Carcinoma;   Recurrent Plasma Cell Myeloma;   Recurrent Prostate Carcinoma;   Recurrent Rectal Carcinoma;   Recurrent Skin Carcinoma;   Recurrent Thyroid Gland Carcinoma;   Recurrent Uterine Corpus Carcinoma;   Refractory Lymphoma;   Refractory Malignant Solid Neoplasm;   Refractory Plasma Cell Myeloma;   Skin Carcinoma;   Thyroid Gland Carcinoma;   Uterine Corpus Cancer
    Interventions:   Drug: Adavosertib;   Drug: Afatinib;   Drug: Afatinib Dimaleate;   Drug: Binimetinib;   Drug: Capivasertib;   Drug: Copanlisib;   Drug: Copanlisib Hydrochloride;   Drug: Crizotinib;   Other: Cytology Specimen Collection Procedure;   Drug: Dabrafenib;   Drug: Dabrafenib Mesylate;   Drug: Dasatinib;   Drug: Defactinib;   Drug: Defactinib Hydrochloride;   Drug: Erdafitinib;   Drug: FGFR Inhibitor AZD4547;   Drug: Ipatasertib;   Other: Laboratory Biomarker Analysis;   Drug: Larotrectinib;   Drug: Larotrectinib Sulfate;   Biological: Nivolumab;   Drug: Osimertinib;   Drug: Palbociclib;   Biological: Pertuzumab;   Drug: PI3K-beta Inhibitor GSK2636771;   Drug: Sapanisertib;   Drug: Sunitinib Malate;   Drug: Taselisib;   Drug: Trametinib;   Biological: Trastuzumab;   Biological: Trastuzumab Emtansine;   Drug: Ulixertinib;   Drug: Vismodegib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting